Humana (NYSE:HUM) announced its quarterly earnings results on Wednesday. The insurance provider reported $5.03 EPS for the quarter, beating the Zacks’ consensus estimate of $4.58 by $0.45, Briefing.com reports. Humana had a net margin of 4.13% and a return on equity of 22.47%. The business had revenue of $16.24 billion during the quarter, compared to analyst estimates of $16.15 billion. During the same quarter in the previous year, the business posted $4.58 EPS. Humana’s quarterly revenue was up 14.3% on a year-over-year basis. Humana updated its FY19 guidance to $17.75 EPS.
NYSE HUM traded up $2.44 during trading hours on Friday, hitting $317.58. The company’s stock had a trading volume of 1,173,375 shares, compared to its average volume of 1,220,728. Humana has a 52 week low of $225.65 and a 52 week high of $342.03. The company has a market capitalization of $39.82 billion, a PE ratio of 21.83, a price-to-earnings-growth ratio of 1.27 and a beta of 0.85. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.37. The company’s 50-day simple moving average is $277.48 and its two-hundred day simple moving average is $270.93.
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a $0.55 dividend. The ex-dividend date of this dividend is Monday, December 30th. This represents a $2.20 annualized dividend and a yield of 0.69%. Humana’s payout ratio is 15.12%.
A number of research analysts have recently issued reports on the stock. Deutsche Bank started coverage on shares of Humana in a report on Thursday, September 12th. They set a “hold” rating and a $300.00 price objective for the company. BMO Capital Markets lowered shares of Humana from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $345.00 to $290.00 in a report on Monday, September 30th. Citigroup upped their target price on shares of Humana from $340.00 to $350.00 and gave the stock a “buy” rating in a report on Thursday. Canaccord Genuity reaffirmed a “buy” rating on shares of Humana in a research report on Monday, October 21st. Finally, Piper Jaffray Companies raised their price target on shares of Humana from $315.00 to $341.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $322.63.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Recommended Story: Cash Flow Analysis in Stock Selection
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.